http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
윤현수,노병진,윤성규,강기천,Hyeonsu Yun,Byeongjin Roh,Seong-Kyu Yun,Gichun Kang 한국지반신소재학회 2024 한국지반신소재학회 논문집 Vol.23 No.1
Recently, the frequency and intensity of typhoon-induced wave loading are increasing due to changed marine environments such as climate change. In addition, frequent earthquakes are causing a lot of damage around the world, including in Japan, Chile, Haiti, China, and Indonesia. In Korea, damage from typhoons has also been increasing since the 2000s, and the frequency and intensity of earthquakes are also increasing. Korea is surrounded by sea on three sides, so typhoons can cause a lot of damage to coastal structures, and earthquakes also cause a lot of damage to coastal structures. As such, the frequency and intensity of typhoon-induced wave loading and earthquakes are increasing both domestically and internationally, but there is no research linking typhoons and earthquakes. Therefore, in this study, numerical analysis was performed for a total of four cases by linking typhoon waves and earthquakes to the caisson breakwater. Numerical analysis was performed by applying wave loads in Case 1 and seismic wave in Case 2, seismic wave after wave loads in Case 3, and wave loads after seismic wave in Case 4. As a result of the numerical analysis, it was confirmed that in Case 3 and Case 4, which linked a typhoon and earthquakes, the damage caused by each load increased compared to Case 1 and Case 2 because the load was applied while the existing ground strength was reduced. In addition, it was confirmed that the greatest damage occurred in Case 3, in which seismic wave were applied after the wave loads.
( Hyunhwa Yoon ),( Young Kul Jung ),( Seung Jun Jang ),( Seung Kak Shin ),( Hae Lim Baek ),( Soo Yong Park ),( Min Young Rim ),( Hyeonsu Park ),( In Ku Yo ),( Oh Sang Kwon ),( Yun Soo Kim ),( Duck Joo 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: The combination theraphy with peginterferon and ribavirin has been used to treat chronic hepatitis C for several years in Korea, yet there is a few reports regarding the results of the genotype 2, 3. We evaluated factors influencing SVR in Korean patients with genotype 2 and 3 chronic hepatitis C after combination theraphy conducted at a single center. Methods: This study was performed to investigate the factors that affect sustained virologic response (SVR) who underwent combination theraphy consist of peginterferon and ribavirin. Reptrosepctively, a total of 98 patients untreated genotype 2 and 3 chronic hepatitis C were enrolled and completed the treatment (52 males(53.06%), genotype 2: 96 (97.96%)). Duration of the treatment was 16-24 weeks. Response of the treatment was evaluated by rapid virologic response (RVR), end treatment virologic response (ETR) and sustained virologic response (SVR). Results: The RVR, ETR, SVR were 88.78%, 92.86% and 91.84% respectively. The total number of patients who did not have SVR were 8, of which 3 patients were non responsive to antiviral agents, and 5 patients showed evidence of relapse of HCV infection. Among the 5 patients with relapse, dose was not reduced in 2 patients, whereas dose reduction was done to 3 patients who showed adverse effects, such as hematologic disorders (anemia, leukopenia, thrombocytopenia), poor oral intake, and general weakness. Univariate analysis showed that the RVR was the only independent factor that affected the SVR(odds ratio=11.857, 95% confidence interval: 2.427-57.920, P<0.001). Conclusions: Our study showed that combination theraphy with peginterferon and ribavirin as an initial treatment for genotype 2 and 3 chronic hepatitis C is very effective, and that the SVR rate is significantly associated with the RVR and might be a useful response factor that is readily available in clinical practice, and especially for genotype 2 and 3 patients.
( Seung Kak Shin ),( Young Kul Jung ),( Seung Jun Jang ),( Hae Lim Baek ),( Hyun Hwa Yoon ),( Soo Yong Park ),( Min Young Rim ),( Hyeonsu Park ),( In Ku Yo ),( Oh Sang Kwon ),( Yun Soo Kim ),( Duck Jo 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: Multi-antiviral drug resistance is a major problem in the treatment of patients with chronic hepatitis B (CHB). Tenofovir disoproxil fumarate (TDF) is recommended for ADV or entecavir (ETV). However, until recently TDF was not available in Korea. ADV and ETV combination therapy may be a viable alternative to TDF in patients with either ADV or ETV resistance. This study investigated the efficacy of ADV and ETV combination therapy in patients with multidrug resistance. Methods: Forty-one patients were enrolled and were administered ADV and ETV combination therapy for at least 12 months. Blood was drawn at baseline and at 12, 24, 36, 48, and 60 months after commencing treatment, and virological response was analyzed. Results: After ADV and ETV combination therapy, ALT normalization was 68%, 73%, 80% 90%, and 93% in 12wks, 24wks, 36wks, 48wks, and 60 wks, respectively. HBV DNA reduction was -1.5, -1.8, -1.9, -1.8, and -1.9 log10IU/mL in 12wks, 24wks, 36wks, 48wks, and 60 wks, respectively. 29 of HBeAg positive patients showed the following low HBeAg seroconversion rate: 3%, 7%, and 10% in 24wks, 48wks, and 60wks, respectively. In addition, virological response group showed lower initial HBV DNA level (P=0.014) and lower HBeAg positive rate (P=0.016) compared with non-virological response group. Conclusions: ADV and ETV combination therapy could be considered in selected chronic hepatitis B patients who have low initial HBV DNA level and HBeAg negative status.